Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: Long-term results

Eye

Volumn 23, Issue 12, 2009, Pages 2223-2227

  Sacu, S ^a   Michels, S ^b   Prager, F ^a   Weigert, G ^a   Dunavoelgyi, R ^a   Geitzenauer, W ^a   Pruente, C ^a   Schmidt Erfurth, U ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Age related macular degeneration; Intravitreal bevacizumab; Photodynamic therapy; Triamcinolone acetonide

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PROSPECTIVE STUDIES; TRIAMCINOLONE; VISUAL ACUITY;

EID: 70349773253     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.423     Document Type: Article

References (16)

1. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37: 1929-1934.
2. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996; 37: 855-868.
3. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 5: 1419-1431.
4. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007; 144: 850-857.
5. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-1349.
6. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006; 26: 262-269.
7. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 2007; 27: 432-438.
8. Aisenbrey S, Ziemssen F, Völker M, Gelisken F, Szurman P, Jaissle G et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245: 941-948.
9. Weigert G, Michels S, Sacu S, Weigert G, Polak K, Vécsei-Marlovits PV et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008; 92: 356-360.
10. Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44: 4473-4480.
11. Schmidt-Erfurth UM, Michels S. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. Ophthalmology 2003; 110: 1306-1314.
12. Chang YS, Wu CL, Tseng SH, Kuo PY, Tseng SY. Cytotoxicity of triamcinolone acetonide on human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2007; 48: 2792-2798.
13. Oh J, Jung YS, Kim GS, Oh IK, Rho BK, Huh K. The effect of short-term exposure of triamcinolone acetonide on fibroblasts and retinal pigment epithelial cells. Acta Ophthalmol Scand 2007; 85: 786-790.
14. Antoszyk AN, Tuomi L, Chung CY, Singh A, on behalf of the FOCUS STUDY GROUP. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008; 145: 862-874.
15. Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Ahadi H. Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Eur J Ophthalmol 2008; 18: 297-300.
16. Dhalla MS, Shah GK, Blinder KJ, Ryan Jr EH, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006; 26: 988-993.